Antisense DNAs as targeted therapeutics for cancer: no longer a dream.
Progress in antisense technology has been rapid, and the traditional antisense inhibition of gene expression has now been viewed at a genomic scale. This global view has led to a deeper understanding of the mechanism of action, the elimination of non-specific and undesirable side effects and, ultimately, greater efficacy and reduced toxicity for nucleic acid medicines. Several antisense oligonucleotides are in clinical trials; these are well tolerated and have therapeutic potential. Antisense oligonucleotides are promising molecular medicines with potential to treat human cancer in the foreseeable future.
Cho-Chung
Yoon S
YS
Cellular Biochemistry Section, BRL, CCR, National Cancer Institute, NIH, Bethesda, MD 20892-1750, USA. ChoChung@helix.nih.gov
D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D016373:DNA, Antisense / Q000737:chemistry / Q000627:therapeutic use*; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D020319:Oligodeoxyribonucleotides, Antisense / Q000737:chemistry / Q000627:therapeutic use
D016373:DNA, Antisense; D020319:Oligodeoxyribonucleotides, Antisense